Clinical Trials Logo

Hyperuricemia clinical trials

View clinical trials related to Hyperuricemia.

Filter by:

NCT ID: NCT04070846 Completed - Gout Clinical Trials

Mass Balance Study of [14C]LC350189 in Healthy Volunteers

Start date: February 26, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, single-dose, mass balance study designed to evaluate the absorption, metabolism, and excretion of [14C] radiolabeled LC350189 after oral administration.

NCT ID: NCT04066712 Completed - Gout Clinical Trials

Renal PK Study of LC350189

Start date: November 19, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, parallel-group, multiple-dose study designed to assess the effect of renal impairment on the PK and PD of LC350189.

NCT ID: NCT04060173 Completed - Gout Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

Start date: September 5, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ABP-671 administered orally in subjects with hyperuricemia.

NCT ID: NCT04040816 Completed - Gout Clinical Trials

Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase II, Multicenter, Randomized, Double-blind, Placebo controlled, Multiple Dose study to evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients with Hyperuricemia.

NCT ID: NCT03990363 Completed - Clinical trials for Chronic Kidney Disease

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

SAPPHIRE
Start date: July 23, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to establish the dose of verinurad combined with allopurinol 300 mg once daily that will elicit the desired response; ie, reduction in urinary albumin to creatinine ratio (UACR) at 6 months.

NCT ID: NCT03934099 Completed - Gout Clinical Trials

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

Start date: December 2, 2019
Phase: Phase 2
Study type: Interventional

The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.

NCT ID: NCT03927677 Completed - Gout Clinical Trials

The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.

Start date: November 5, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the PK, PD, safety, and tolerability of LC350189 and colchicine when administered alone and in combination in healthy subjects.

NCT ID: NCT03923868 Completed - Clinical trials for Hyperuricemia or Gout

D-0120 Safety and PK/PD Study in China

Start date: April 18, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

It is a randomized, double-blind, placebo-controlled, multiple-administration, multiple-dose, dose-escalating, phase Ib/IIa clinical study to evaluate the safety, tolerability, PK and PD of D-0120 in healthy subjects and hyperuricemia patients (gout or asymptomatic) in China.

NCT ID: NCT03921736 Completed - Hypertension Clinical Trials

Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.

Start date: January 10, 2000
Phase: Phase 4
Study type: Interventional

The aim was to assess the effect of estrogen-progestin therapy (EPT) on serum levels of uric acid (SUA) and its precursors: xanthine (X) and hypoxanthine (HX) and on uric acid (UA) renal excretion in hypertensive postmenopausal women treated with an angiotensin-converting enzyme inhibitor (ACEI) or thiazide diuretic (HCTZ).

NCT ID: NCT03906006 Completed - Gout Clinical Trials

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

Start date: October 17, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of ABP-671 administered orally in healthy volunteers.